Butterfly Network, Inc.
NYSE: BFLY·Burlington, Massachusetts·CIK 0001804176
- Price
- $5.71
- Base IV
- $0.60
Valuation snapshot
At $5.71, the price is above even our bull case of $2.10.
Values per share, from an .
- No growth
- …
- Loading earnings power
- Base case
- $0.60
- 10% of the price · range $0.03–$2.10
- Price vs base case
- 859% above
- $5.71 against $0.60
- Base case · our researched forecast, 2026-10-30See the research ↗
- Price vs base · derived: price − base caseWhat the price expects ↗
- Price · StockValuer price feed, 2026-11-16 closeno link today
The price has fallen 24.0% since this valuation was struck on 2026-10-30, so some of the gap opened up after these figures were set.
Whisker on the base case runs bear $0.03 to bull $2.10. Values per share.
Price against each value
- Bear case
- $0.03
- Price 16,530% above
- No growth
- …
- —
- Base case
- $0.60
- Price 859% above
What does Butterfly Network do?
Butterfly Network makes handheld ultrasound probes and companion apps that let clinicians image a patient's heart, lungs, or abdomen at the bedside on a phone or tablet instead of booking an imaging suite.
It brought in $123.3M of sales in the 12 months to Sep 2026.
Led by Joseph M. DeVivo, President, Chief Executive Officer, and Chairman of the Board since 2023. Form 8-K Current Report
- Industry
- Healthcare
- Based in
- Burlington, Massachusetts
- Trades on
- NYSE as BFLY
Here is where each dollar a customer pays ends up. For every $1 of sales in the 12 months to Sep 2026, it spent about $1.44, so it lost 44¢ on each dollar. The biggest cost is sales, marketing and admin, 74¢ of every dollar.
- Making what it sells30¢
- Research and development32¢
- Sales, marketing and admin74¢
- Everything else it takes to operate11¢
- Interest and other income came back in+3¢
- Lost on each dollar−44¢
Who pays Butterfly Network, and for what?
Butterfly Network makes handheld ultrasound scanners that plug into a smartphone or tablet. Most of its scanners use its own 'Ultrasound-on-Chip' semiconductor. It earns money in three ways: selling the scanners and a cart, charging yearly subscriptions for its imaging and hospital software, and licensing its chip technology to partners such as Midjourney under its 'Butterfly Embedded' program.
Most revenue comes from U.S. hospitals and health systems, individual doctors and other clinicians, medical schools, and veterinarians, with smaller amounts from international distributors, global health groups and technology partners that license its chip.
Product
65%Sales of handheld ultrasound probes (iQ3, iQ+, and the bladder and vet versions) and the Butterfly Move cart, plus some deliveries of chips to a technology partner.
Butterfly iQ3 handheld ultrasound probeImage: Butterfly Network Software and other services
35%Yearly software subscriptions for individual users, the Compass hospital software platform, education offerings, and licensing fees from Butterfly Embedded chip partnerships. Licensing drove most of the 2025 growth in this line.
Where its work physically happens, beyond headquarters:
- Benchmark Ayutthaya Plant — Bang Pa-in, Thailand. This contract-manufacturing site produces, tests, and ships many Butterfly probes, making it central to product supply and exposing Butterfly to single-manufacturer concentration risk.
How is the business doing?
Sales grew from $46.3M in 2020 to $97.6M in 2025, about 16% a year.
It still spends more to run the business than it brings in: an operating loss of 47¢ per sales dollar, narrower than $3.49 in 2020.
It used $27.6M more cash than it generated in the 12 months to Sep 2026, paid for out of savings or new money.
What does management say it's aiming for?
Butterfly says it exists to make ultrasound imaging available and useful wherever patients receive care, not just in hospital imaging departments.
“democratize healthcare by increasing access and use of ultrasound information wherever care is being delivered”
Who is responsible for the plan?
- Joseph M. DeVivoPresident, Chief Executive Officer, and Chairman of the Board
He oversees the company's global business operations, strategic direction, and corporate execution. Butterfly Network develops and commercializes handheld semiconductor-based ultrasound devices and cloud-connected software solutions for healthcare providers.
- Steve CashmanExecutive Vice President and Chief Business Officer
He oversees global sales, marketing, product management, and corporate strategy. These commercial functions drive customer adoption and revenue generation across Butterfly's portable ultrasound devices and software subscriptions.
- Victor KuSenior Vice President and Chief Technology Officer
He leads the company's global technology strategy, product development, and innovation roadmap. The company's commercial medical hardware and imaging products depend on proprietary semiconductor-based Ultrasound-on-Chip technology and software engineering.
Roles checked November 14, 2026.
What management says it is working on now:
Grow the core hospital and clinician business
Management wants more health systems and medical schools to use its handheld probes at the bedside, backed by its Compass software, which helps hospitals manage ultrasound across many departments.
Butterfly Network 10-K for fiscal year 2025License the chip to other companies
Through Butterfly Embedded, the company licenses its ultrasound chip to partners working in markets that don't compete with its own. Embedded revenue rose to $10.8 million in Q2 2026 from $2.0 million a year earlier, mainly because of the Midjourney partnership.
Butterfly Network 10-Q for quarter ended June 30, 2026Expand into home care and veterinary markets
The company is preparing its first commercial Home & Community Care rollout for the second half of 2026 and is selling a vet version of its newest probe in about 20 international markets.
Butterfly Network Q2 2026 results press release (8-K Exhibit 99.1)Build a network of AI partners and next-generation chips
Its 'Butterfly Garden' program lets outside developers build AI tools for its devices, and three partner tools are expected to go on sale by year-end. Management also lists a next-generation probe and new P5 and Apollo chips as upcoming launches, without giving dates.
Butterfly Network Q2 2026 results press release (8-K Exhibit 99.1)Keep spending under control
Management lists financial discipline as a core part of its strategy. It wants to narrow losses, and it expects higher-margin software to make up a larger share of revenue over time.
Butterfly Network 10-K for fiscal year 2025
- Revenue, Full year 2026
- $119 million to $123 million (about 22% to 26% growth)
- Butterfly Network Q2 2026 results press release (8-K Exhibit 99.1)
- Adjusted EBITDA, Full year 2026
- Loss of $19 million to $23 million
- Butterfly Network Q2 2026 results press release (8-K Exhibit 99.1)
What's changing right now?
Growth is picking up. In Q3 2026 it sold 52% more than a year earlier. The year before, quarters averaged 27%.
Its operating margin is wider than a year ago: a loss of 42¢ per sales dollar, against a loss of $1.63.
Since Jul 2026 the share price has fallen 26%, from $7.75 to $5.71.
Recently
September 30, 2026
Software and services revenue, quarterly changed to $17.0M
Butterfly Q3 2026 resultsSeptember 30, 2026
Product revenue, quarterly changed to $15.6M
Butterfly Q3 2026 resultsJuly 30, 2026
Quarterly revenue growth, year over year changed to 39.5%
Butterfly Q2 2026 Form 10-Q
Coming up
Targeted for Q3 2026
FedRAMP certification
Butterfly said it was on track for FedRAMP certification, a U.S. government security approval for cloud software that could open sales to federal agencies.
Butterfly Network Q2 2026 results press release (8-K Exhibit 99.1)Second half of 2026; revenue expected Q4 2026
First Home & Community Care rollout
The company plans its first commercial launch of ultrasound for home and community care settings, with first revenue expected in the fourth quarter.
Butterfly Network Q2 2026 results press release (8-K Exhibit 99.1)August to December 2026
Key supplier and distributor contracts up for renewal
Its agreements with Cardinal Health (August 31), Benchmark (October 1) and TSMC (December 31, with renewal provisions) were due to expire in 2026. The renewal terms could affect costs and supply.
Butterfly Network 10-K for fiscal year 2025By end of 2026
AI partner tools go on sale
Three AI tools built by outside developers in the Butterfly Garden program are expected to become commercially available.
Butterfly Network Q2 2026 results press release (8-K Exhibit 99.1)
Our own estimate moved too: the base case went from $0.64 to $0.60 a share between our last two valuations. The biggest reason: Software and services revenue, quarterly moved from an unreported prior value to $17.0M, as reported in Butterfly Q3 2026 results.
What could go wrong?
No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.
Still losing money
Butterfly lost $77.1 million in 2025 and says it expects losses to continue for several years. Its cash fell from $150.5 million at the end of 2025 to $124.7 million by June 2026.
From the company's own filingsWould hit how much of each sale it keepsButterfly Network 10-Q for quarter ended June 30, 2026
Growth depends heavily on a few licensing partners
Much of the recent growth came from chip licensing, mainly Midjourney, and one customer made up more than 10% of revenue in the latest quarter. If a partner leaves or pays less, revenue could drop sharply.
From the company's own filingsWould hit how fast sales growButterfly Network 10-Q for quarter ended June 30, 2026
Reliance on a small number of suppliers
Key parts come from limited or single suppliers. Its contracts with chipmaker TSMC, manufacturer Benchmark and distributor Cardinal Health all come up in 2026, and any disruption could delay or raise the cost of making probes.
From the company's own filingsWould hit how much of each sale it keepsButterfly Network 10-K for fiscal year 2025
Strong competition and fast-changing technology
Butterfly competes with larger medical device companies, and new technology could make its devices outdated. Hospital buying groups have also pushed prices down.
From the company's own filingsWould hit how fast sales growButterfly Network 10-K for fiscal year 2025
Medical and data regulation
Its products need approvals from health regulators such as the FDA, and new uses like at-home scanning may require clinical trials. Privacy, cybersecurity and responsible-AI rules add cost and legal risk.
From the company's own filingsWould hit how fast sales growButterfly Network 10-K for fiscal year 2025
Ongoing lawsuits
The company faces a securities class action, shareholder lawsuits and other litigation. Legal costs were a large part of its $3.6 million in 'other' expenses in Q2 2026.
From the company's own filingsWould hit how much of each sale it keepsButterfly Network 10-Q for quarter ended June 30, 2026
Product revenue grew only from $14.6 million to $15.6 million between the third quarters of 2025 and 2026.
From our researchWould hit how fast sales growButterfly Q3 2026 results
Share count is still growing
Diluted shares grew 5.7% year on year. This valuation uses today's share count, not tomorrow's — continued dilution would spread the same value across more shares.
From the numbers
Is it a good business?
From 2021 to 2025 it earned between -61% and -7% on its shareholders' equity, a median of -43%.
Over 6 years its operating margin ranged from $3.49 to 89¢ per sales dollar, a median of $2.42. Gross margin ran from $1.32 to 60¢.
It bought back shares: the count fell 76% from 2021 to 2025, so each remaining share owns a bigger slice.
What might it be worth?
Net debt is excluded: The reported balance sheet does not yet establish a complete debt figure. The per-share value may change when resolved. No earlier published debt figure is available.
The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .
Today a share costs $5.71. Our put its value between $0.03 and $2.10, with $0.60 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .
Bear case, $0.03
Despite a strong recent rise in sales, this scenario assumes new partnerships bring uneven revenue and the company only barely becomes profitable.
Base case, $0.60
Following strong recent sales growth but continuing losses, this scenario assumes partnerships keep sales rising while the larger business gradually becomes profitable.
Bull case, $2.10
After a sharp recent rise in sales, this scenario assumes new partners and larger customers keep sales growing quickly and turn the company into a strongly profitable business.
Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.
Why the gap?
The price expects far more than we do.Price above value: 859%
For Butterfly Network to be worth today's $5.71, sales would need to grow about 88.2% a year. We assume 15.4%. Over the last 5 years, sales grew 15.8% a year.
Keep in mind: investors are likely paying for things this model leaves out, such as new businesses or many more years of fast growth.
Do you think sales can grow 88.2% a year?
Try your own numbersWe're not very sure of this range: it scores 37 out of 100 on our checks. The weakest point is scenario dispersion.
Test the assumptions
Our base value of $0.60 rests on three assumptions. Change any of them to see how the value per share responds.
- Revenue growth, 5-year average15.4%
- Operating margin14.0%
- Long-term growth rate2.5%
This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.
Base estimate
$0.60 -89.6%


